Nobuhiro Asai1, Hiroki Watanabe2, Arufumi Shiota3, Hideo Kato4, Daisuke Sakanashi5, Mao Hagihara6, Yusuke Koizumi7, Yuka Yamagishi8, Hiroyuki Suematsu9, Hiroshige Mikamo10. 1. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: asai.nobuhiro.039@mail.aichi-med-u.ac.jp. 2. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: watanabe.hiroki.769@mail.aichi-med-u.ac.jp. 3. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: shiota@aichi-med-u.ac.jp. 4. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: katou.hideo.233@mail.aichi-med-u.ac.jp. 5. Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: saka74d@aichi-med-u.ac.jp. 6. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: hagimao@aichi-med-u.ac.jp. 7. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: ykoizumi@aichi-med-u.ac.jp. 8. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: y.yamagishi@mac.com. 9. Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: hsuemat@aichi-med-u.ac.jp. 10. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi, Japan; Department of Infection Control and Prevention, Aichi Medical University Hospital, Aichi, Japan. Electronic address: mikamo@aichi-med-u.ac.jp.
Abstract
BACKGROUND: The Japanese Respiratory Society recently updated its prognostic guidelines for pneumonia, recommending that pneumonia severity be evaluated using the sequential organ failure assessment (SOFA) and quick SOFA (qSOFA) scoring systems in a therapeutic strategy flowchart. However, the efficacy and accuracy of these tools are still unknown. METHODS: All patients with community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP) who were admitted to the study institution between 2014 and 2017 were enrolled in this study. Pneumonia severity on admission was evaluated by A-DROP, CURB-65, PSI, I-ROAD, qSOFA, and SOFA scoring systems. Prognostic factors for 30-day mortality were also analyzed. RESULTS: This study included 406 patients, 257 male (63%) and 149 female (37%). The median age was 79 years (range 19-103 years). The 30-day and in-hospital mortality rates were both 5%. With respect to the diagnostic value of the predictive assessments for 30-day mortality, the area under the receiver operating characteristic curve (AUROC) value for the SOFA score was 0.769 for CAP patients and 0.774 for HCAP patients. Further, the AUROC values for the SOFA score in CAP and HCAP patients with a qSOFA score ≥2 were 0.829 and 0.784, respectively, for 30-day mortality. CONCLUSIONS: qSOFA and SOFA scores were able to correctly evaluate the severity of CAP and HCAP.
BACKGROUND: The Japanese Respiratory Society recently updated its prognostic guidelines for pneumonia, recommending that pneumonia severity be evaluated using the sequential organ failure assessment (SOFA) and quick SOFA (qSOFA) scoring systems in a therapeutic strategy flowchart. However, the efficacy and accuracy of these tools are still unknown. METHODS: All patients with community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP) who were admitted to the study institution between 2014 and 2017 were enrolled in this study. Pneumonia severity on admission was evaluated by A-DROP, CURB-65, PSI, I-ROAD, qSOFA, and SOFA scoring systems. Prognostic factors for 30-day mortality were also analyzed. RESULTS: This study included 406 patients, 257 male (63%) and 149 female (37%). The median age was 79 years (range 19-103 years). The 30-day and in-hospital mortality rates were both 5%. With respect to the diagnostic value of the predictive assessments for 30-day mortality, the area under the receiver operating characteristic curve (AUROC) value for the SOFA score was 0.769 for CAP patients and 0.774 for HCAPpatients. Further, the AUROC values for the SOFA score in CAP and HCAPpatients with a qSOFA score ≥2 were 0.829 and 0.784, respectively, for 30-day mortality. CONCLUSIONS: qSOFA and SOFA scores were able to correctly evaluate the severity of CAP and HCAP.
Authors: Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel Journal: Hum Vaccin Immunother Date: 2021-11-10 Impact factor: 3.452
Authors: Peter D Sottile; David Albers; Peter E DeWitt; Seth Russell; J N Stroh; David P Kao; Bonnie Adrian; Matthew E Levine; Ryan Mooney; Lenny Larchick; Jean S Kutner; Matthew K Wynia; Jeffrey J Glasheen; Tellen D Bennett Journal: J Am Med Inform Assoc Date: 2021-10-12 Impact factor: 4.497
Authors: Min Woo Kang; Jayoun Kim; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Seung Seok Han Journal: Crit Care Date: 2020-02-06 Impact factor: 9.097